The Occurence of Inflammation and Oxidative Stress in Lung Diseases

NCT00512967 | Completed

• 1 other identifier: MEC 03-112
• Study Type: observational
• Target: 76
• Locations: 1 country
• Sites: 1

Brief Summary

Reactive oxygen species (ROS) are suggested to play a pivotal role in ILD. Little is known, however, about the endogenous antioxidant levels in ILD that can offer protection against ROS. It is expected that the high amount of ROS present in ILD will reduce the antioxidant levels. Therefore, antioxidant therapy to strengthen this reduced antioxidant defense might be efficacious in ILD treatment. Since ROS are capable of initiating and mediating inflammation, antioxidant therapy might also mitigate elevated inflammation. A candidate for antioxidant therapy is the flavonoid quercetin that is known for its anti-oxidative and anti-inflammatory capacities. The aim of the present study is to determine the antioxidant and inflammatory status in ILD, i.e. sarcoidosis and idiopathic pulmonary fibrosis (IPF). Furthermore, to evaluate the possible anti-inflammatory effects of antioxidants, the effect of quercetin will be examined on the ex vivo LPS-induced cytokine production in ILD

Conditions

Interstitial Lung Diseases; Sarcoidosis; Idiopathic Pulmonary Fibrosis; COPD

Keywords

oxidative stress; antioxidants; inflammation; quercetin

Study Arms (4)

sarcoidosis

21 onset patients, non-treated

IPF

15 IPF patients, partially treated

COPD

15 COPD patients within 24 hours after their last exacerbation

controls

25 healthy controls, matched for age and gender

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

lung patients visiting the out-patient clinic of the Academic Hospital Maastricht

You may qualify if:

• clinical diagnosis of pulmonary sarcoidosis, IPF or COPD
• no treatment for sarcoidosis
• last exacerbation not more than 24 hours ago for COPD
• healthy controls
• no smoking for sarcoidosis and IPF

You may not qualify if:

• pregnancy
• use of vitamins or food supplements
• clinical diagnosis (and treatment) of other diseases
• symptoms of sarcoidosis in other organs besides the lung

Sponsors & Collaborators

• Maastricht University Medical Center: lead
• ZonMw: The Netherlands Organisation for Health Research and Development: collaborator

Study Sites (1)

Maastricht University

Maastricht, 6224 LH, Netherlands

Location

Biospecimen

Retention: SAMPLES WITH DNA

blood samples were collected

MeSH Terms

Conditions

Lung Diseases, Interstitial; Sarcoidosis; Idiopathic Pulmonary Fibrosis; Pulmonary Disease, Chronic Obstructive; Inflammation

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Hypersensitivity, Delayed; Hypersensitivity; Immune System Diseases; Pulmonary Fibrosis; Lung Diseases, Obstructive; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Aalt Bast, PhD

  Maastricht University

  STUDY CHAIR

• Agnes W Boots, PhD

  Maastricht University

  PRINCIPAL INVESTIGATOR

• Guido R Haenen, PhD

  Maastricht University

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: July 19, 2007
• First Posted: August 8, 2007
• Study Start: September 1, 2005
• Study Completion: June 1, 2006
• Last Updated: February 24, 2017

Record last verified: 2008-02

Locations

NL (1)